Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
DURHAM, N.C., Oct. 25, 2016 -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that an abstract from its pulmonary research and development efforts will be presented at the 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Florida, October 27 through 29, 2016.
The accepted abstract is titled “PULMONARY AEROSOL DEPOSITION IN CHILDREN WITH CYSTIC FIBROSIS FOLLOWING TRANSNASAL DELIVERY OF HYPERTONIC SALINE” and is poster number 459. The poster will include deposition, safety, and tolerability data from the trial of a novel transnasal delivery device to deliver hypertonic saline to the lungs of children with Cystic Fibrosis. It will be presented on Thursday, October 27th between 11:15 am and 1:45 pm during the formal poster session.
The transnasal delivery device used in the study was developed and tested with the support of the Cystic Fibrosis Foundation.
About Parion Sciences
Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or airway. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and is leveraging our scientific expertise in epithelial biology to expand our platforms and novel chemical compounds into new indications to treat mucosal defects. Parion has received support and grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation Therapeutics, Inc. For more information, please see our website at www.Parion.com.
Contact: Joe Schachle Chief Operating Officer (919)313-1194 [email protected]
